Evommune Initiates Phase 2 Trial of EVO756, an Oral MRGPRX2 Antagonist, in Chronic Inducible Urticaria
First of two near-term Phase 2 clinical trials to be initiated in Chronic Urticaria Chronic Inducible Urticaria (CIndU) trial will evaluate EVO756 in approximately... Read more.
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium
SAN JOSE, Calif., Sept. 3, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology... Read more.
Morphy’s Brings Fresh-To-Market Trove of Rare and Historical Firearms and Militaria to Auction, Sept. 10-12
Featured: Set of 4 Francolini-engraved Colt SAA Revolvers, 184 lots of NFA arms, WWII German weapons, presentation swords, 1860 ‘Henry’ rifle, gorgeous... Read more.
REPUBLIC OF URUGUAY – ANNOUNCEMENT OF TENDER OFFER
MONTEVIDEO, Uruguay, Sept. 3, 2024 /PRNewswire/ — The Republic of Uruguay (“Uruguay“), announced today the commencement of an offer to purchase... Read more.
RE+ 2024: Ampace to Spotlight UniC Series and Introduce Industry-First Technology to the Americas for the First Time
ANAHEIM, Calif., Sept. 2, 2024 /PRNewswire/ — With the rapid development of technology, innovative energy solutions are becoming the focus of global attention.... Read more.
Quanta Computer Enters into a Strategic Investment in Vuzix in Support of Long-Term Waveguide Design and Supply Partnership
Vuzix to receive a $20 million dollar investment in 3 tranches from Quanta Computer, one of the world’s largest ODMs Quanta investment to support the expansion... Read more.
Viomi Technology Co., Ltd Announces Completion of Certain IoT@Home Businesses Divestment
GUANGZHOU, China, Aug. 31, 2024 /PRNewswire/ — Viomi Technology Co., Ltd (“Viomi” or the “Company”) (NASDAQ: VIOT), a leading technology... Read more.
2nd Tsinghua Global Youth Dialogue Opens
BEIJING, Aug. 31, 2024 /PRNewswire/ — On August 29th, the Second Tsinghua Global Youth Dialogue was held at Tsinghua University. The theme “Harmony and... Read more.
Grit Biotechnology Receives U.S. FDA Clearance of Investigational New Drug Application for GT201, a genetically engineered TIL, following its Chinese IND Approval
SHANGHAI, Aug. 30, 2024 /PRNewswire/ — Grit Biotechnology, a leading clinical-stage cell therapy company focusing on tumor-infiltrating lymphocyte (TIL) therapies,... Read more.
HYZON, NEW WAY AND RECOLOGY JOIN U.S. DEPARTMENT OF ENERGY AT CLEAN ENERGY EVENT TO SHOWCASE NORTH AMERICA’S FIRST HYDROGEN FUEL CELL ELECTRIC REFUSE COLLECTION VEHICLE
Hyzon’s Hydrogen Fuel Cell Technology Highlighted in Heavy-Duty Fuel Cell Electric Vehicle Displays OAKLAND, Calif., Aug. 30, 2024 /PRNewswire/ — Hyzon... Read more.